Karbis

Candesartan cilexetil, the active ingredient in Karbis, is a Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is used to treat hypertension and heart failure in adult patients.

GNH USA supplies Karbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karbis belongs to the Angiotensin II receptor blocker class and is indicated for cardiovascular conditions. - Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and myocardial infarction. - Heart failure: improves symptoms, decreases hospital admissions, and enhances survival in patients with reduced ejection fraction.

Adverse reactions may occur with any medication.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity, often transient. - Fatigue: feeling of tiredness or reduced energy. - Hyperkalemia: elevated blood potassium levels detected in laboratory tests.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Acute renal impairment: sudden decrease in kidney function, indicated by rising creatinine. - Severe hypotension: markedly low blood pressure causing faintness or shock. - Hepatic injury: abnormal liver enzymes or jaundice. - Neutropenia: marked reduction in neutrophil count, increasing infection risk.

Before initiating therapy, certain safety considerations are recommended. - Monitor blood pressure: ensure adequate control and avoid excessive lowering. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: especially when combined with potassium‑sparing agents. - Use caution in severe hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Candesartan may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes): increased risk of hypotension, hyperkalemia, and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use can lead to additive blood pressure reduction and elevated potassium.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Rifampin: enzyme induction can lower candesartan plasma concentrations, reducing efficacy.